The IRA, BMS’ Big Cuts, First WHIM Approval | BioSpace

The Weekly BioSpace News Podcast

Earlier this week, a federal judge in New Jersey added fuel to the ongoing legal battle between Big Pharma and the government over the Inflation Reduction Act. The judge on Monday dismissed claims from Johnson & Johnson and Bristol Myers Squibb that Medicare’s drug price negotiations program is unconstitutional.

The big news last week also involved BMS, which announced it will let go 2,200 people by the end of 2024 in what the company is calling a “strategic productivity initiative.” Layoffs are already underway in New Jersey, California and elsewhere, and may be related to the pharma giant’s recent M&A spending spree.

Elsewhere around the industry, Q1 earnings season rolls on, with Sanofi and AstraZeneca also announcing cuts to their pipeline, while Gilead, Merck, and Lilly all touted numbers that exceeded expectations.

Finally, on the…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks